Fulton Breakefield Broenniman LLC Invests $215,000 in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

Fulton Breakefield Broenniman LLC acquired a new position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) in the 4th quarter, HoldingsChannel reports. The fund acquired 23,579 shares of the company’s stock, valued at approximately $215,000.

Several other large investors also recently modified their holdings of PHAT. Principal Financial Group Inc. grew its position in Phathom Pharmaceuticals by 11.9% in the 3rd quarter. Principal Financial Group Inc. now owns 11,801 shares of the company’s stock valued at $122,000 after purchasing an additional 1,259 shares during the period. Wellington Management Group LLP lifted its stake in Phathom Pharmaceuticals by 1.8% during the 3rd quarter. Wellington Management Group LLP now owns 99,810 shares of the company’s stock valued at $1,035,000 after acquiring an additional 1,797 shares in the last quarter. Barclays PLC lifted its stake in Phathom Pharmaceuticals by 22.4% during the 3rd quarter. Barclays PLC now owns 13,235 shares of the company’s stock valued at $137,000 after acquiring an additional 2,422 shares in the last quarter. Allworth Financial LP lifted its stake in Phathom Pharmaceuticals by 15.3% during the 4th quarter. Allworth Financial LP now owns 22,580 shares of the company’s stock valued at $206,000 after acquiring an additional 3,000 shares in the last quarter. Finally, Inspirion Wealth Advisors LLC lifted its stake in Phathom Pharmaceuticals by 16.6% during the 4th quarter. Inspirion Wealth Advisors LLC now owns 35,134 shares of the company’s stock valued at $322,000 after acquiring an additional 5,000 shares in the last quarter. Institutional investors and hedge funds own 99.01% of the company’s stock.

Insider Transactions at Phathom Pharmaceuticals

In other news, CFO Molly Henderson sold 3,435 shares of Phathom Pharmaceuticals stock in a transaction on Monday, April 8th. The stock was sold at an average price of $11.10, for a total transaction of $38,128.50. Following the sale, the chief financial officer now directly owns 95,263 shares in the company, valued at approximately $1,057,419.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO Molly Henderson sold 3,435 shares of Phathom Pharmaceuticals stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $11.10, for a total value of $38,128.50. Following the completion of the sale, the chief financial officer now owns 95,263 shares of the company’s stock, valued at approximately $1,057,419.30. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Terrie Curran sold 16,851 shares of Phathom Pharmaceuticals stock in a transaction dated Friday, March 22nd. The stock was sold at an average price of $9.11, for a total value of $153,512.61. Following the completion of the sale, the insider now directly owns 410,784 shares of the company’s stock, valued at approximately $3,742,242.24. The disclosure for this sale can be found here. Company insiders own 24.10% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC restated a “buy” rating and set a $26.00 price objective on shares of Phathom Pharmaceuticals in a research note on Friday.

Phathom Pharmaceuticals Price Performance

NASDAQ:PHAT traded up $0.08 during trading hours on Friday, hitting $9.18. 370,890 shares of the company traded hands, compared to its average volume of 725,758. Phathom Pharmaceuticals, Inc. has a one year low of $6.07 and a one year high of $17.02. The firm’s 50-day simple moving average is $9.85 and its 200-day simple moving average is $8.70.

Phathom Pharmaceuticals (NASDAQ:PHAT) last released its earnings results on Thursday, March 7th. The company reported ($0.80) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.12. The business had revenue of $0.68 million for the quarter, compared to the consensus estimate of $0.93 million. During the same quarter in the previous year, the firm earned ($1.33) earnings per share. As a group, analysts forecast that Phathom Pharmaceuticals, Inc. will post -4.22 EPS for the current fiscal year.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.